ergothioneine

Small moleculeexperimental

Ergothioneine is a naturally occurring amino acid and is a thiourea derivative of histidine, containing a sulfur atom on the imidazole ring. This compound occurs in relatively few organisms, notably actinomycetota, cyanobacteria, and certain fungi. Ergothioneine was discovered by Charles Tanret in 1909 and named after the ergot fungus from which it was first purified, with its structure being determined in 1911. — Wikipedia

Clinical trial activity

5 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Aug 31, 2018 (NCT03641404)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetAntioxidant

    antioxidant

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06487546N/AOct 1, 2024Stanford University
NCT05190432N/ANov 10, 2021Blue California Co, Moorgreen Hospital, Southampton
NCT05042674N/ASep 20, 2021Natural Immune Systems Inc, NIS Labs
NCT04556032N/ASep 9, 2020Blue California Co, Midwest Center for Metabolic and Cardiovascular Research
NCT03641404Phase 3Aug 31, 2018National University of Singapore
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Blue California CoFor profit2012020
Midwest Center for Metabolic and Cardiovascular ResearchAcademic/Hospital1112020
Moorgreen Hospital, SouthamptonAcademic/Hospital1112021
National University of SingaporeAcademic/Hospital1112018
Natural Immune Systems IncFor profit1112021
NIS LabsFor profit1012021
Stanford UniversityAcademic/Hospital1112024
7 organizations
Page 1 / 1